Order Breast
Cancer
IndexOrder Breast Cancer IndexOrder Breast Cancer Index

Not Another Minute Prescribing Treatment That May Not Benefit Her

Endocrine Therapy Is Associated With Side Effects And More Serious Health Risks – Is Prolonged Treatment Going To Benefit Her?

It is important to determine whether the treatment is likely to reduce her risk of recurrence before exposing her to potential risks associated with extended treatment. In the ATLAS Trial2 (extended TAM) 16 recurrences were prevented at the cost of:3,4

Bone Toxicity Remains A Concern For Extending Patients On Aromatase Inhibitors (AIs)5,6

  • Significantly increased rates of bone pain, osteoporosis, and bone fractures despite a majority of patients being on bisphosphonates, vitamin D/calcium supplementation.5
  • Twice as many bone fractures (n=133) as recurrences (n=67) in the letrozole group.5
  • In an independent study, major fractures were associated with increased mortality in women with osteoporosis.6

Breast Cancer Index® Predicts Whether She Is Likely To Benefit From Extended Endocrine Therapy To Help Determine Whether Continuing Treatment Is Right For Her.7,8

The Predictive Power Of Breast Cancer Index

References: 1. Hershman et al. Breast Cancer Res Treat. 2011; 126(2): 529-537. 2. Davies C et al., Lancet. 2013;381(9869):805-16. 3. Nolvadex prescribing information. http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088661.pdf. 4. Conzen, SD. Managing the side effects of tamoxifen. In: UpToDate, Dizon DS (Ed), UpToDate, Waltham, MA. (Accessed on March 11, 2015.). 5. Goss PE et al. N Engl J Med 2016 DOI:10.1056/NEJMoa1604700. 6. Bliuc D et al. JAMA 2009; 301(5):513-521. 7. Sgroi DC et al. J Natl Cancer Inst 2013;105:1036-1042. 8. Bartlett et al. Annals of Oncol 2019 doi: 10.1093/annonc/mdz289.

Back To All
Back to Top